Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

3.700 +0.060 (+1.65%)
Delayed Quote Updated: 11:50 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about LENZ Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript ↗
Prescription growth surged 45% in July after telehealth launch. 
Via The Motley Fool
Topics Earnings
News headline image
LENZ Therapeutics Q2 Earnings Call Highlights ↗
LENZ Therapeutics (NASDAQ:LENZ) reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity... 
Via MarketBeat
Topics Earnings
News headline image
Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing ↗
RadNet runs a large outpatient imaging network and is building DeepHealth, its AI radiology platform. The upside is clearer if advanced imaging growth and digital health expansion can develop without... 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock ↗
Via Chartmill
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
LENZ Therapeutics Q1 Earnings Call Highlights ↗
LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption... 
Via MarketBeat
Topics Earnings
News headline image
Lenz (LENZ) Q1 2026 Earnings Call Transcript ↗
Lenz (LENZ) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗
It failed to meet expectations for its final quarter of 2025. 
Via The Motley Fool
News headline image
Why Lenz Therapeutics Stock Crashed Today ↗
Is it time to throw away your reading glasses? Maybe not just yet. 
Via The Motley Fool
News headline image
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗
LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗
LENZ Therapeutics Q3 2025 results show an 80% revenue beat and narrower loss as it launches its new FDA-approved vision treatment, VIZZ™. 
Via Chartmill
News headline image
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People ↗
LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025. 
Via Benzinga
News headline image
Lenz (LENZ) Q2 Revenue Jumps 604% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 19, 2025 ↗
 
Via Benzinga
News headline image
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships ↗
LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval. 
Via Benzinga
News headline image
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why LENZ Therapeutics Stock Hit A New 52-Week High Today ↗
Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug application. 
Via Benzinga
News headline image
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024 ↗
LENZ stock results show that LENZ Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says ↗
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.